SCHEMBL5875692

SCHEMBL5875692

Nc1ncc(S(=O)(=O)c2ccc(Cl)cc2)s1

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA3 P0DMS8 1/20 0.76
SLC6A3 Q01959 1/20 0.76
MEN1 O00255 2/20 0.50
KMT2A Q03164 2/20 0.50
ALDH1A1 P00352 2/20 0.48
CYP3A4 P08684 1/20 0.48
MAPK1 P28482 1/20 0.48
LOXL2 Q9Y4K0 6/20 0.47
LOX P28300 2/20 0.47
SMN1; SMN2 Q16637 2/20 0.43
MAPT P10636 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
GCK P35557 1/20 0.43
GCKR Q14397 1/20 0.43
KDM4E B2RXH2 1/20 0.42
PKM P14618 1/20 0.42
HTT P42858 1/20 0.42
CA12 O43570 1/20 0.41
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Thiazolsulfone SCHEMBL152559 0.86 ADORA3 (1.00) ADORA3SLC6A3MEN1KMT2AALDH1A1
SCHEMBL1062382 0.83 ADORA3 (0.75) ADORA3SLC6A3LOXL2LOXKCNH2
SCHEMBL1062638 0.80 ADORA3 (0.69) ADORA3SLC6A3MEN1KMT2AALDH1A1
SCHEMBL5875745 0.80 ADORA3 (0.69) ADORA3SLC6A3MEN1KMT2AALDH1A1
SCHEMBL5875686 0.80 ADORA3 (0.49) ADORA3SLC6A3MEN1KMT2AALDH1A1
SCHEMBL9048270 0.74 ADORA3 (0.62) ADORA3SLC6A3LOXL2LOXMAPT
SCHEMBL28327828 0.72 ADORA3 (0.55) ADORA3SLC6A3ALDH1A1LOXL2LOX
SCHEMBL5875599 0.72 ADORA3 (0.58) ADORA3SLC6A3KMT2AALDH1A1LOXL2
SCHEMBL9046843 0.70 ADORA3 (0.57) ADORA3SLC6A3ALDH1A1LOXL2LOX
SCHEMBL9049940 0.70 ADORA3 (0.56) ADORA3SLC6A3LOXL2LOXKCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-2006504796-A 2006-02-09 JP claimed
EP-1551815-A1 THIAZOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS Pfizer Products Inc. (US) 2005-07-13 EP claimed
US-20040152747-A1 Thiazole compounds for treatment of neurodegenerative disorders PFIZER INC 2004-08-05 US claimed
WO-2004033439-A1 THIAZOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS PFIZER PRODUCTS INC. (US) 2004-04-22 WO claimed
US-20040152747-A1 Thiazole compounds for treatment of neurodegenerative disorders PFIZER INC 2004-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040152747-A1 Thiazole compounds for treatment of neurodegenerative disorders APP, PARK7, IAPP ADORA3 130/4885SLC6A3 1100/4885MEN1 1289/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.